Amgen Boosts Bid for Onyx to $130 a Share

Amgen Boosts Bid for Onyx to $130 a Share Play

Aug. 7 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Cristina Alesci reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

blog comments powered by Disqus